Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ATRC
stocks logo

ATRC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
139.29M
+12.08%
-0.053
-33.56%
138.67M
+12.18%
-0.107
-23.81%
152.21M
+11.8%
-0.050
+150%
Estimates Revision
The market is revising Upward the revenue expectations for AtriCure, Inc. (ATRC) for FY2025, with the revenue forecasts being adjusted by 0.51% over the past three months. During the same period, the stock price has changed by 10.94%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.51%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-31.27%
In Past 3 Month
Stock Price
Go Up
up Image
+10.94%
In Past 3 Month
Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 52.60 USD with a low forecast of 45.00 USD and a high forecast of 64.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 52.60 USD with a low forecast of 45.00 USD and a high forecast of 64.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.250
sliders
Low
45.00
Averages
52.60
High
64.00
Current: 39.250
sliders
Low
45.00
Averages
52.60
High
64.00
Canaccord
William Plovanic
Buy
maintain
$51 -> $53
2025-07-30
Reason
Canaccord
William Plovanic
Price Target
$51 -> $53
2025-07-30
maintain
Buy
Reason
Canaccord analyst William Plovanic raised the firm's price target on AtriCure to $53 from $51 and keeps a Buy rating on the shares. The firm said they reported a very solid Q2, with strength across the rest of the business more than offsetting further degradation of US EPi-Sense/Hybrid. The target increase reflects comp group multiple expansion and increased expectations.
BTIG
Buy
upgrade
$52 -> $54
2025-07-30
Reason
BTIG
Price Target
$52 -> $54
2025-07-30
upgrade
Buy
Reason
BTIG raised the firm's price target on AtriCure to $54 from $52 and keeps a Buy rating on the shares. The company reported a "wow" quarter, exceeding expectations on the top and bottom as revenue growth accelerated to 16.5%, with results driven by new product launches across the Pain and Appendage Management franchises, the analyst tells investors in a research note.
Citizens Capital Markets
Daniel Stauder
Buy
Reiterates
$60
2025-04-02
Reason
Citizens Capital Markets
Daniel Stauder
Price Target
$60
2025-04-02
Reiterates
Buy
Reason
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$66 → $52
2025-03-28
Reason
Canaccord Genuity
William Plovanic
Price Target
$66 → $52
2025-03-28
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on AtriCure to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model folloing the company's Investor Day that both reiterated its 2025 guidance and provided an aspirational LRP that included three-year objectives as well as targets for 2030.
Needham
Mike Matson
Strong Buy
Reiterates
$51
2025-03-27
Reason
Needham
Mike Matson
Price Target
$51
2025-03-27
Reiterates
Strong Buy
Reason
JP Morgan
Lilia-Celine Lozada
Buy
Maintains
$51 → $46
2025-03-27
Reason
JP Morgan
Lilia-Celine Lozada
Price Target
$51 → $46
2025-03-27
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for AtriCure Inc (ATRC.O) is -172.00, compared to its 5-year average forward P/E of -57.13. For a more detailed relative valuation and DCF analysis to assess AtriCure Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-57.13
Current PE
-172.00
Overvalued PE
-31.97
Undervalued PE
-82.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
1249.63
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8524.77
Undervalued EV/EBITDA
-6025.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.92
Current PS
0.00
Overvalued PS
9.21
Undervalued PS
2.63
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 521.1% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 521.1% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ATRC News & Events

Events Timeline

(ET)
2025-10-29
16:03:56
AtriCure Projects FY25 EPS Between (26c) and (23c), Below Consensus of (36c)
select
2025-10-29
16:03:11
AtriCure Announces Q3 Earnings Per Share of 1 Cent, Below Consensus Estimate of 12 Cents
select
2025-10-28 (ET)
2025-10-28
08:23:39
AtriCure begins enrollment of first patient in BoxX-NoAF clinical study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-25NASDAQ.COM
Wall Street Analysts Predict AtriCure (ATRC) May Surge 36.3%: Here's How to Invest

  • Stock Performance and Analyst Predictions: AtriCure (ATRC) shares have risen 3.5% recently, with Wall Street analysts projecting a mean price target of $51.44, suggesting a potential upside of 36.3%. The price targets range from $40.00 to $64.00, indicating varying levels of optimism among analysts.

  • Skepticism Towards Price Targets: While price targets are popular among investors, they can often mislead, as analysts may set overly optimistic targets due to business incentives. A low standard deviation in price targets indicates strong agreement among analysts, but it should not be the sole basis for investment decisions.

  • Earnings Estimate Revisions: Analysts have shown increased optimism regarding AtriCure's earnings, with a 32.9% rise in the Zacks Consensus Estimate for the current year. This trend in earnings estimate revisions is correlated with potential stock price movements.

  • Zacks Rank and Investment Outlook: AtriCure holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates. This ranking, along with a strong track record, suggests a favorable outlook for the stock despite the skepticism surrounding price targets.

[object Object]
Preview
9.5
11-06NASDAQ.COM
Key Metrics Insights on AtriCure's (ATRC) Revised Q3 Earnings

  • AtriCure's Financial Performance: AtriCure (ATRC) reported $134.27 million in revenue for Q3 2025, a 15.8% increase year-over-year, with an EPS of -$0.01, significantly improving from -$0.17 a year ago.

  • Market Expectations and Surprises: The revenue exceeded the Zacks Consensus Estimate by 2.09%, while the EPS surprise was +90.91%, indicating stronger-than-expected performance.

  • Stock Performance: AtriCure's shares have declined by 4.02% over the past month, contrasting with a 0.95% increase in the Zacks S&P 500 composite, and the stock holds a Zacks Rank #2 (Buy).

  • Investment Insights: Zacks Investment Research highlights a satellite-based communications firm as a top stock pick, projecting significant revenue growth in the trillion-dollar space industry, alongside other high-potential stocks.

[object Object]
Preview
8.0
10-28NASDAQ.COM
Fascinating ATRC Put and Call Options Set for December 19th

  • Put Contract Overview: The $35.00 put contract has a bid of 10 cents, allowing investors to buy ATRC shares at a cost basis of $34.90, which is a 4% discount from the current price of $36.41. There is a 62% chance the contract may expire worthless, offering a potential 0.29% return on cash commitment.

  • Call Contract Overview: The $40.00 call contract has a bid of 5 cents, enabling investors to sell ATRC shares at that price, which represents a 10% premium over the current stock price. If the contract expires worthless, investors could retain their shares and earn a 0.14% additional return.

  • Volatility Insights: The implied volatility for the put contract is 61%, while the call contract has an implied volatility of 68%. The actual trailing twelve-month volatility is calculated at 49%.

  • YieldBoost Concept: The article discusses the concept of YieldBoost, which refers to the additional returns investors can earn from options contracts, highlighting the potential returns from both the put and call contracts discussed.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is AtriCure Inc (ATRC) stock price today?

The current price of ATRC is 39.25 USD — it has increased 8.1 % in the last trading day.

arrow icon

What is AtriCure Inc (ATRC)'s business?

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

arrow icon

What is the price predicton of ATRC Stock?

Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 52.60 USD with a low forecast of 45.00 USD and a high forecast of 64.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is AtriCure Inc (ATRC)'s revenue for the last quarter?

AtriCure Inc revenue for the last quarter amounts to 134.27M USD, increased 15.84 % YoY.

arrow icon

What is AtriCure Inc (ATRC)'s earnings per share (EPS) for the last quarter?

AtriCure Inc. EPS for the last quarter amounts to -0.01 USD, decreased -94.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for AtriCure Inc (ATRC)'s fundamentals?

The market is revising Upward the revenue expectations for AtriCure, Inc. (ATRC) for FY2025, with the revenue forecasts being adjusted by 0.51% over the past three months. During the same period, the stock price has changed by 10.94%.
arrow icon

How many employees does AtriCure Inc (ATRC). have?

AtriCure Inc (ATRC) has 1300 emplpoyees as of December 05 2025.

arrow icon

What is AtriCure Inc (ATRC) market cap?

Today ATRC has the market capitalization of 1.95B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free